# US 2008/0187521 A1 · Use Of Medulliadrenal Chromaffin Cells Or Peptide Functional Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187521 A1
- Document ID: US20080187521A1
- Status: Published application
- Kind: A1
- Application number: 11/576,061
- Filed: 2004-09-27
- Published: 2008-08-07
- Earliest claimed: 2004-09-27
- Assignees: Yilong Xue
- Inventors: Yilong Xue; Guanghua Liu
- Web page: https://patentgrep.com/patent/US20080187521A1

## CPC

- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new use of medulliadrenal chromaffin cells or opioid-peptidergic cells, in particular to their use for treating and/or relieving withdrawal syndrome resulting from drug addiction or drug abuse.

## Claims

### Claim 1

Use of medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering in the manufacture of a product for treating and/or relieving withdrawl syndrome resulting from drug addiction or abuse.

### Claim 2

A method for treating and/or relieving withdrawl syndrome resulting from drug addiction or abuse, comprising administering by injection to a drug addict or abuser medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering.

### Claim 3

A product for treating or relieving withdrawl syndrome, comprising medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering, in particular APA microencapsulated medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering.

### Claim 4

A medicine of microencapsulated bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering for treating or relieving withdraw syndrome, characterized in that said medicine is prepared by the following steps:
(1) mixing the bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering with a sodium alginate solution of 10-20 g/L to form a suspension, said suspension containing 0.1-1010 cells per liter;
(2) dispersing the suspension of step (1) into a calcium chloride or calcium lactate solution of 80-120 mmol/L in the form of droplets of 150-1000 μm in diameter using a spraying device, the two liquids being in such a proportion that the resulting mixture contains 0.1-1×108 cells per liter, leaving to stand for 5-20 minutes, discarding the supernatant after complete precipitation, to obtain the calcium alginate bead precipitates comprising bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering;
(3) adding the precipitates from step (2) into a polylysine solution of 0.3-0.7 g/L in such a proportion that the resulting mixture contains 0.2-2×108 cells per liter, mixing thoroughly, leaving to stand for 5-20 minutes, discarding the supernatant after complete precipitation, to obtain the precipitates;
(4) adding the precipitates from step (3) into a sodium alginate solution of 1.0-2.0 g/L in such a proportion that the resulting mixture contains 0.2-2×108 cells per liter, mixing thoroughly, leaving to stand for 3-15 minutes, discarding the supernatant after complete precipitation, to obtain the precipitates;
(5) adding the precipitates from step (4) into a sodium citrate solution of 40-70 mmol/L in such a proportion that the resulting mixture contains 0.2-2×108 cells per liter, mixing thoroughly, leaving to stand for 5-20 minutes, discarding the supernatant after complete precipitation, to obtain the precipitates of microencapsulated bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering;
(6) washing the precipitates from step (5) by adding them into a sodium chloride solution of 9 g/L, finally transferring the precipitates into a cell culture, culturing and storing as a medicine of microencapsulated bovine medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering for treating or relieving withdrawl syndrome.

### Claim 5 (depends on 1)

Use according to claim 1, wherein the medulliadrenal chromaffin cells or opioid-peptidergic cells obtained e.g. by genetic engineering may be derived from mammal such as human, cattle, sheep, pig, rat or mouse medulliadrenal chromaffin cells or genetically engineered cells.

### Claim 6 (depends on 5)

Use according to claim 5, wherein the medulliadrenal chromaffin cells are bovine medulliadrenal chromaffin cells.

### Claim 7 (depends on 1)

Use according to claim 1, wherein the medulliadrenal chromaffin cells are used in microencapsulated form.

### Claim 8 (depends on 7)

Use according to claim 7, wherein the medulliadrenal chromaffin cells are APA-microencapsulated bovine medulliadrenal chromaffin cells.

### Claim 9 (depends on 1)

Use according to claim 1, wherein the microencapsulated bovine medulliadrenal chromaffin cells have a purity of at least 80%.
